Iulia Karlsson appointed new CEO of FarmPharma

Report this content

An extraordinary board meeting of DBP's subsidiary FarmPharma AB, which took place yesterday at 14:00 CET at the company's office in Uppsala, elected Dr Iulia Karlsson to be the new CEO of the company. Igor Lokot, former CEO of FarmPharma, became chairman of the board and the number of board members increased to four.

"Fast and efficient development of FarmPharma requires a lot of commitment and energy, as well as creative innovation, I am therefore very pleased that Dr Iulia Karlsson is the new CEO of the company", - commented Igor Lokot, CEO of Double Bond Pharmaceutical and Chairman of the board at Farm Pharma, "Iulia Karlsson has made great contributions to the development of DBP in recent years, where she worked in preclinical development, regulatory affairs, marketing and business development."

More about FarmPharma: FarmPharma AB is a subsidiary of Double Bond Pharmaceutical. The company is active in the development and distribution of veterinary products, and their first product is for the prevention and treatment of bacterial and viral infections in cattle without the use of antibiotics. For more info: http://www.farmpharma.se/

Video presentation: https://youtu.be/e1cPSC2PC70

More about Iulia Karlsson: Iulia is a Ph. D. in Medical Biosciences from the Swedish University of Agricultural Sciences and has studied Veterinary Medicine and Biochemistry during her education.

For more info, contact
Igor Lokot, CEO

Homepage: http://www.doublebp.com/

E-mail: info@doublebp.com 

Blog: http://blog.doublebp.com

Follow us on LinkedIn, Facebook and Twitter!

Information on Double Bond Pharmaceutical International AB

DBP is a pharmaceutical company with the primary focus on development of therapies against cancer based on the company’s own developed drug delivery technology BeloGal®. The company was granted Orphan Drug Designation status by European Medicines Agency (EMA) in June 2015 for its first product, SA-033, for treatment of hepatoblastoma. Double Bond Pharmaceutical acquired rights to Temodex, a drug registered in Belarus for treatment of brain tumours, in October 2015, and was granted Orphan Drug Designation status by EMA for in July 2016 for this formulation of temozolomide for the treatment of glioma. The formulation is now being further developed for registration in EU and globally and has a working name SI-053 in DBP pipeline.



Documents & Links